Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review

期刊论文
发表日期：

2024年7月27日

查看全文

Laurent Mathiot,
Capucine Baldini,
Octave Letissier,
Antoine Hollebecque,
Rastislav Bahleda,
Anas Gazzah,
Cristina Smolenschi,
Madona Sakkal,
François-Xavier Danlos,
Clémence Henon,
Kristi Beshiri,
Vincent Goldschmidt,
Claudia Parisi,
Anna Patrikidou,
Jean-Marie Michot,
Aurélien Marabelle,
Sophie Postel-Vinay,
Alice Bernard-Tessier,
Yohann Loriot,
Santiago Ponce,
Stéphane Champiat,
Kaïssa Ouali

摘要

Purpose of Review

Antibody–drug conjugates (ADCs) offer a promising path for cancer therapy, leveraging the specificity of monoclonal antibodies and the cytotoxicity of linked drugs. The success of ADCs hinges on precise targeting of cancer cells based on protein expression levels. This review explores the relationship between target protein expression and ADC efficacy in solid tumours, focusing on results of clinical trials conducted between January 2019 and May 2023.

Recent Findings

We hereby highlight approved ADCs, revealing their effectiveness even in low-expressing target populations. Assessing target expression poses challenges, owing to variations in scoring systems and biopsy types. Emerging methods, like digital image analysis, aim to standardize assessment. The complexity of ADC pharmacokinetics, tumour dynamics, and off-target effects emphasises the need for a balanced approach.

Summary

This review underscores the importance of understanding target protein dynamics and promoting standardized evaluation methods in shaping the future of ADC-based cancer therapies.